Nasdaq · CIK 0001762303
RCEL AVITA Medical, Inc.
Insider trading from SEC Form 4. Last filing Aug 29, 2025. Close $13.21 on Oct 9, 2026, +304% from the 52-week low and -1% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
RCELOct 9, 2026 · close 13.21
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at AVITA Medical, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 55Moderate | Robert McNamara director buy | $45k 10,000 shares | +13% | +3% from low-69% from high | |
| 56Moderate | David D O'Toole CFO buy | $9,040 2,000 shares | +7% | +7% from low-68% from high | |
| 41Moderate | Robert McNamara director buy | $50k 10,000 shares | +15% | +15% from low-65% from high | |
| 41Moderate | David D O'Toole CFO buy | $9,620 2,000 shares | +7% | +30% from low-61% from high | |
| 61Notable | Robert McNamara director buy | $91k 11,000 shares | +24% | 0% from low-41% from high | |
| 39Weak | David D O'Toole CFO buy | $9,900 1,000 shares | +4% | +17% from low-29% from high | |
| 43Moderate | Robert McNamara director buy | $101k 10,000 shares | +28% | +17% from low-29% from high | |
| 39Weak | David D O'Toole CFO buy | $10k 1,000 shares | +4% | +21% from low-27% from high | |
| 23Weak | Suzanne Crowe director buy | $6,391 486 shares | +1% | +43% from low0% from high | |
| 30Weak | David D O'Toole CFO buy | $12k 975 shares | +4% | +30% from low-7% from high |
Transactions
The last 28 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 28, 2025 | Robert McNamara director | POpen-market purchase Common Stock | +10,000 | $4.50 | $45k | 86,771 | Aug 29, 2025 |
| Aug 26, 2025 | David D O'Toole CFO | POpen-market purchase Common Stock | +2,000 | $4.52 | $9,040 | 31,657 | Aug 26, 2025 |
| Aug 19, 2025 | Robert McNamara director | POpen-market purchase Common Stock | +10,000 | $5.00 | $50k | 76,771 | Aug 20, 2025 |
| Aug 12, 2025 | David D O'Toole CFO | POpen-market purchase Common Stock | +2,000 | $4.81 | $9,620 | 29,657 | Aug 12, 2025 |
| Jan 21, 2025 | Suzanne Crowe director | AGrant or award Common Stock | +10,022 | - | - | 46,934 | Jun 5, 2025 |
| Jan 21, 2025 | Cary Guy Vance director | AGrant or award Common Stock | +10,022 | - | - | 35,771 | Jun 5, 2025 |
| Jan 21, 2025 | Jan Stern Reed director | AGrant or award Common Stock | +10,022 | - | - | 51,011 | Jun 5, 2025 |
| Jan 21, 2025 | Robert McNamara director | AGrant or award Common Stock | +10,022 | - | - | 66,771 | Jun 5, 2025 |
| Jan 21, 2025 | Jeremy Curnock Cook director | AGrant or award Common Stock | +10,022 | - | - | 39,836 | Jun 5, 2025 |
| Jan 21, 2025 | Lou Panaccio director | AGrant or award Common Stock | +10,022 | - | - | 56,428 | Jun 5, 2025 |
| Jan 21, 2025 | James Corbett CEO | AGrant or award Stock Options (Right to Buy)derivative | +520,000 | $0.00 | $0 | 520,000 | Jun 5, 2025 |
| Jan 21, 2025 | Suzanne Crowe director | AGrant or award Stock Options (Right to Buy)derivative | +4,295 | $0.00 | $0 | 4,295 | Jun 5, 2025 |
| Jan 21, 2025 | Jeremy Curnock Cook director | AGrant or award Stock Options (Right to Buy)derivative | +4,295 | $0.00 | $0 | 4,295 | Jun 5, 2025 |
| Jan 21, 2025 | Robert McNamara director | AGrant or award Stock Options (Right to Buy)derivative | +4,295 | $0.00 | $0 | 4,295 | Jun 5, 2025 |
| Jan 21, 2025 | Jan Stern Reed director | AGrant or award Stock Options (Right to Buy)derivative | +4,295 | $0.00 | $0 | 4,295 | Jun 5, 2025 |
| Jan 21, 2025 | Cary Guy Vance director | AGrant or award Stock Options (Right to Buy)derivative | +4,295 | $0.00 | $0 | 4,295 | Jun 5, 2025 |
| Jan 21, 2025 | Lou Panaccio director | AGrant or award Stock Options (Right to Buy)derivative | +4,295 | $0.00 | $0 | 4,295 | Jun 5, 2025 |
| May 30, 2025 | David D O'Toole CFO | AGrant or award Common Stock | +1,923 | $4.78 | $9,186 | 27,657 | Jun 2, 2025 |
| Mar 6, 2025 | Robert McNamara director | POpen-market purchase Common Stock | +11,000 | $8.30 | $91k | 56,749 | Mar 10, 2025 |
| Feb 20, 2025 | Robert McNamara director | POpen-market purchase Common Stock | +10,000 | $10.09 | $101k | 45,749 | Feb 20, 2025 |
| Feb 20, 2025 | David D O'Toole CFO | POpen-market purchase Common Stock | +1,000 | $9.90 | $9,900 | 25,734 | Feb 20, 2025 |
| Feb 19, 2025 | David D O'Toole CFO | POpen-market purchase Common Stock | +1,000 | $10.25 | $10k | 24,734 | Feb 19, 2025 |
| Dec 9, 2024 | Suzanne Crowe director | POpen-market purchase Common Stock | +486 | $13.15 | $6,391 | 36,912 | Jan 29, 2025 |
| Jan 21, 2025 | Nicole Kelsey Chief Legal Officer | AGrant or award Stock Options (Right to Buy)derivative | +65,000 | $0.00 | $0 | 65,000 | Jan 22, 2025 |
| Jan 21, 2025 | David D O'Toole CFO | AGrant or award Stock Options (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jan 22, 2025 |
| Nov 29, 2024 | David D O'Toole CFO | AGrant or award Common Stock | +785 | $7.83 | $6,147 | 22,759 | Dec 5, 2024 |
| Dec 5, 2024 | David D O'Toole CFO | POpen-market purchase Common Stock | +475 | $12.53 | $5,952 | 23,234 | Dec 5, 2024 |
| Dec 5, 2024 | David D O'Toole CFO | POpen-market purchase Common Stock | +500 | $12.40 | $6,200 | 23,734 | Dec 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jeremy Curnock Cookdirector
- James CorbettCEO
- Suzanne Crowedirector
- Nicole KelseyChief Legal Officer
- Robert McNamaradirector
- David D O'TooleCFO
- Lou Panacciodirector
- Jan Stern Reeddirector
- Cary Guy Vancedirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.